Nonmyeloablative allogeneic transplantation (NMAT) infrequently cures active chemoresistant, bulky, or aggressive Bcell lymphoma (B-cell non-Hodgkin lymphoma [B-NHL]). We hypothesized that 90Y-ibritumomab tiuxetan–based NMAT would facilitate early cytoreduction in such patients promoting improved longterm disease control by the allogeneic graft. Forty high-risk B-NHL patients with persistent di...

UNLABELLED Intensification of the conditioning regimen with a radioactively labeled anti-CD66 antibody is feasible before allogeneic stem cell transplantation. The use of radioimmunotherapy may deliver a significant dose of radiation to the kidneys. We therefore studied the incidence and clinical picture of bone marrow transplantation (BMT) nephropathy in our patients receiving radioimmunothera...

The primary aim of our study was to compare the need for periinterventional on-demand analgesia when water for injection (WFI) was replaced with glucose 5% (G5) for 90Y-resin microsphere administration. METHODS Forty-one patients who received 77 radioembolization procedures with G5 (2014-2015) were retrospectively matched with 41 patients (77 radioembolization procedures) who received radioem...

Human gliomas, especially of low-grade type, have been shown to express high-affinity somatostatin receptor type 2 (J-C. Reubi et al., Am. J. Pathol, 134: 337-344, 1989). We enrolled seven low-grade and four anaplastic glioma patients in a pilot study using the diffusible peptidic vector 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC) for receptor targeting. The radiopharmakon was locoregion...

Background and purposeSystemic molecular radiotherapy utilizes internal irradiation by radionuclide-labeled tumor-targeting agents with the potential to destroy (micro-)metastases. However, doses that are applicable in solid tumors do not reach levels nessecary for tumor control. Thus, combination of external is a promising treatment strategy, as enhanced can be delivered without minor overlapp...

Background: The functional changes that occur over time in the liver following 90Y-radioembolization (RE) using personalized dosimetry (PD) remain to be investigated. Methods: November 2016–October 2019: we retrospectively included hepatocellular carcinoma (HCC) patients treated by 90Y-glass RE PD, who underwent hepatobiliary scintigraphy (HBS) at baseline and 15 days, 1, 2, 3, 6 months after R...

Stevenson, Bedford, Dolphin, Purrott, Lloyd, Hill, Hill, Gumpel, Williams, Scott, Ramsey, Bruckner, and Fearn (1973) reported that high chromosome aberration yields in lymphocytes were found in those patients treated with injections of 198Au or 90Y for rheumatoid conditions ofthe knee when radioactivity had leaked along the lymphatics to the inguinal lymph nodes. This leakage and the consequent...

Favourable results have been obtained in the treatment of persistent joint effusion with radioactive agents (e.g. Ansell, Crook, Mallard, and Bywaters, 1963; Virkkunen, Krusius, and Heiskanen, 1967; Delbarre, Cayla, Roucayrol, Menkes, Aignan, and Ingrand, 1970; Oka, Rekonen, Ruotsi, and Seppalii, 1971). The future of this kind of radiotherapy is largely dependent on whether the ionizing radiati...

Hepatocellular carcinoma (HCC) is a disease usually diagnosed in its advanced-stage, and is frequently not amenable to curative surgical treatment. Also, HCC is resistant to chemotherapy and less vulnerable to radiation therapy compared to normal hepatic parenchyma. Both of these facts render the efficacy of adjuvant and palliative treatments problematic. Selective internal radiation therapy (S...